Eating Disorder Screen Results and GLP ‐1 Awareness, Interest, and Use in a Nationally Representative Sample of Adults in U.S. Households
International Journal of Eating Disorders · 2026-10 · 59 (10) · 2217-2225
DOI: 10.1002/eat.70103 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Eating Disorders, online erschienen am 19.06.2026. Verfasst von Jaclyn A Siegel und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health, NORC at the University of Chicago, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Feeding and Eating Disorders, Glucagon-Like Peptide 1, Glucagon-Like Peptide-1 Receptor Agonists, Health Knowledge, Attitudes, Practice. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Objective
Glucagon‐like peptide‐1 receptor agonists (GLP‐1s) have experienced exponential growth in prescriptions over the last few years. Pervasive advertising and cultural discussion about these medications have worried body image, weight stigma, and eating disorder researchers. Research is lacking about GLP‐1 awareness, interest, access, and use among individuals who have a positive screen on an eating disorder screener.
Method
Leveraging AmeriSpeak's nationally representative panel of U.S. adults, we conducted a cross‐sectional study ( N = 1309) to examine the associations between screening positive on the Eating Disorder Screen for Primary Care (ESP) and GLP‐1 awareness, interest, and use.
Results
Roughly 10% of participants reported past or present GLP‐1 medication use. Women were more likely than men to report interest in taking GLP‐1 medications for weight loss. Both women and men who screened positive on the ESP were more likely to report awareness of these medications, interest in using GLP‐1s for weight loss, and trying to access GLP‐1s through telehealth pharmacies without speaking with a doctor. Women who screened positive were also more likely to have considered taking GLP‐1s to manage a health condition and to have spoken with their doctor about taking GLP‐1s for weight loss. There was no statistically significant difference between individuals who had never taken a GLP‐1 and those who had ever taken a GLP‐1 on ED screening status.
Discussion
A positive screen on an eating disorder screener was associated with interest and attempts to access GLP‐1s for weight loss, especially for women. Clinicians working with individuals with eating disorders or body image concerns should discuss GLP‐1s with clients. Enhanced safeguards for prescribing GLP‐1s, particularly through telehealth platforms, are suggested.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Public Health, NORC at the University of Chicago, Chicago, Illinois, USA.
- Department of Public Health, Social Data Collaboratory, NORC at the University of Chicago, Chicago, Illinois, USA.
ORCID-Profile: Jaclyn A Siegel, Elizabeth A Mumford, Alex Kresovich, Sherry Emery, Chandria Jones
Zitieren
APA
Siegel, J. A., Mumford, E. A., Kresovich, A., Emery, S., & Jones, C. (2026). Eating Disorder Screen Results and GLP ‐1 Awareness, Interest, and Use in a Nationally Representative Sample of Adults in U.S. Households. International Journal of Eating Disorders, 59(10), 2217-2225. https://doi.org/10.1002/eat.70103
Vancouver
Siegel JA, Mumford EA, Kresovich A, Emery S, Jones C. Eating Disorder Screen Results and GLP ‐1 Awareness, Interest, and Use in a Nationally Representative Sample of Adults in U.S. Households. International Journal of Eating Disorders. 2026;59(10):2217-2225. doi:10.1002/eat.70103
BibTeX
@article{Siegel2026,
author = {Siegel, Jaclyn A and Mumford, Elizabeth A and Kresovich, Alex and Emery, Sherry and Jones, Chandria},
title = {Eating Disorder Screen Results and GLP ‐1 Awareness, Interest, and Use in a Nationally Representative Sample of Adults in U.S. Households},
journal = {International Journal of Eating Disorders},
year = {2026},
volume = {59},
number = {10},
pages = {2217--2225},
doi = {10.1002/eat.70103}
}
EUVIMED